Characterization of murine Caraparu Bunyavirus liver infection and immunomodulator-mediated antiviral protection

Brinton, Margo A.; Gavin, Edith I.; Lo, Woo-Kuen; Pinto, Angelo J.; Morahan, Page S.

doi:10.1016/0166-3542(93)90005-4

Cited by 9 publications

(5 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Resistance to the IFN system was previously described for three members of Bunyaviridae family, CARV (Brinton et al, 1993), Rift Valey fever virus (Bouloy et al, 2001), and Bunyamwera virus (Weber et al, 2002;Léonard et al, 2006). Brinton et al (1993), corroborating the results obtained by us, observed that CARV resisted antiviral action of immmunomodulators, such as IFN-␣ and IFN-␤. However, the escape mechanism of CARV was not studied by the authors.…”

Section: Discussionsupporting

confidence: 87%

“…Similarly to OROV, CARV (Group C serogroup), GMAV (Guama serogroup), GROV (California encephalitis and Bunyamwera serogroups) and TCMV (Anopheles A serogroup) have also been associated with febrile illness in humans. These viruses are transmitted by mosquitoes and cause disease mainly in the South America countries (Brinton et al, 1993;Tavares-Neto et al, 2004;Jonkers et al, 1968;March and Hetrick, 1967;Travassos da Rosa et al, 1997;Iversson et al, 1993;Iversson, 1994). An antiviral therapy, if available, would be a very helpful intervention, reducing symptoms and disease period of OROV fever as well as of those febrile illnesses caused by other orthobunyaviruses.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

In vitro and in vivo studies of the Interferon-alpha action on distinct Orthobunyavirus

et al. 2007

View full text Add to dashboard Cite

Oropouche, Caraparu, Guama, Guaroa and Tacaiuma viruses (Orthobunyavirus genus) cause human febrile illnesses and/or encephalitis. To achieve a therapeutical agent to prevent and/or treat these diseases we evaluated the antiviral action of Interferon-alpha (IFN-alpha) on these orthobunyaviruses. In vitro results showed that all the studied orthobunyaviruses are susceptible to antiviral action of IFN-alpha, but this susceptibility is limited and dependent on both concentration of drug and treatment period. In vivo results demonstrated that IFN-alpha present antiviral action on Oropouche and Guaroa viruses when used as a prophylactic treatment. Moreover, a treatment initiated 3h after infection prevented the death of Guaroa virus infected-mice. Additionally, mortality of mice was related to the migration and replication of viruses in their brains. Our results suggest that IFN-alpha could be potentially useful in the prevention of diseases caused by Oropouche virus and in the prevention and/or treatment of diseases caused by Guaroa virus.

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Introductionmentioning

confidence: 99%

In vitro and in vivo studies of the Interferon-alpha action on distinct Orthobunyavirus

et al. 2007

View full text Add to dashboard Cite

show abstract

“…41 A previous in vivo study showed that the CARV was susceptible to antiviral action of RBV, and this is at variance with our results. 5 A possible explanation is based on the experimental model used. In that study, 4-to 6-week-old B6C3F1 mice were inoculated intraperitoneally with CARV and died after they had developed coagulative liver necrosis.…”

Section: Discussionmentioning

confidence: 99%

“…They are transmitted by mosquitoes and cause disease mainly in residents of the Amazon region of Brazil. [5][6][7][8] Due to the high attack rates of OROV epidemics and to the debilitating nature and duration of symptoms of the clinical syndromes caused by this and other Brazilian orthobunyaviruses, antiviral therapy, if available, would become a very helpful intervention.…”

Section: Introductionmentioning

confidence: 99%

In Vitro and in Vivo Studies of Ribavirin Action on Brazilian Orthobunyavirus

Livonesi¹,

Sousa²,

Badra³

et al. 2006

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Oropouche, Caraparu, Guama, Guaroa, and Tacaiuma are viruses (genus Orthobunyavirus) that cause human febrile illnesses and encephalitis. The goal of this study was to evaluate the antiviral action of ribavirin on these orthobunyaviruses to achieve a therapeutical agent to treat the diseases caused by these viruses. In vitro results showed that ribavirin (50 microg/mL) had antiviral activity only on the Tacaiuma virus. Addition of guanosine in the culture reversed the antiviral effect of ribavirin on Tacaiuma virus, suggesting that ribavirin inhibited this virus by reducing the intra-cellular guanosine pool. Moreover, ribavirin was not an effective drug in vivo because it was unable to inhibit the death of the mice or virus replication in the brain. The results suggest that ribavirin has no antiviral activity on the Oropouche, Caraparu, Guama, Guaroa, or Tacaiuma viruses; consequently, ribavirin would not be a good therapeutical agent to treat these arboviruses.

show abstract

“…Similar to Oropouche virus, Caraparu, Guama, Guaroa, and Tacaiuma viruses have also been associated with febrile illness in humans. They are transmitted by mosquitoes and cause disease mainly in residents of the Amazon region of Brazil [4][5][6][7] . Due to the high attack rates of Oropouche fever epidemics and to the debilitating nature and duration of symptoms of the clinical syndromes caused by this and other Brazilian orthobunyaviruses , antiviral therapy, if available, would become a very helpful intervention.…”

Section: Introductionmentioning

confidence: 99%

In vitro Study of Antiviral Activity of Mycophenolic Acid on Brazilian Orthobunyaviruses

Livonesi

Sousa²,

Figueiredo³

2007

Intervirology

View full text Add to dashboard Cite

Objective: Oropouche, Caraparu, Guama, Guaroa and Tacaiuma are ssRNA viruses that belong to the genus Orthobunyavirus and have been associated with human febrile illnesses and/or encephalitis. In this study, we evaluated the antiviral action of mycophenolic acid (MPA) on theseorthobunyaviruses to achieve a therapeutic agent to treat the diseases caused by these viruses. Methods: The in vitro antiviral evaluation to MPA was done by using plaque assay at different periods of treatment. Results: Results showed that MPA at a concentration of 10 µg/ml has significant antiviral activity on Tacaiuma virus when treatment was initiated either 24 h before or 2 h after viral infection. Moreover, MPA has an inhibitory effect on Guama virus replication, but only when treatment was initiated before cell infection. Addition of guanosine in the culture reverted the inhibitory effect of MPA on Tacaiuma and Guama viruses, suggesting that the antiviral activity of this substance was via depletion of the intracellular guanosine pool. Conclusion: Our results suggest that MPA would not be a good therapeutic agent to treat the diseases caused by Oropouche, Caraparu, Guama, Guaroa, and Tacaiuma viruses.

show abstract

Characterization of murine Caraparu Bunyavirus liver infection and immunomodulator-mediated antiviral protection

Cited by 9 publications

References 33 publications

In vitro and in vivo studies of the Interferon-alpha action on distinct Orthobunyavirus

In vitro and in vivo studies of the Interferon-alpha action on distinct Orthobunyavirus

In Vitro and in Vivo Studies of Ribavirin Action on Brazilian Orthobunyavirus

In vitro Study of Antiviral Activity of Mycophenolic Acid on Brazilian Orthobunyaviruses

Contact Info

Product

Resources

About